Found 9 matching trials
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
PHASE1This is a phase 1, multi-centre, sequential cohort, open-label, dose-escala...
Location
Dana Farber Cancer Institute
ANG1005 in Patients With Recurrent High-Grade Glioma
PHASE2This is a Phase 2 study to see if an investigational drug, ANG1005, can shr...
Location
Moores UC San Diego Cancer Center
Expanded Access to ANG1005 for Individual Patients
N/AThis is an expanded access study with ANG1005 treatment for two individual ...
Status
No Longer Available
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
PHASE2The purpose of this study is to assess the efficacy, safety, and tolerabili...
Location
Univ. of California San Diego
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
PHASE2This is a Phase 2 study to see if an investigational drug, ANG1005, can shr...
Location
University of Arizona Cancer Center
GRN1005 for Brain Metastases From Breast or Lung Cancer
PHASE2Background:
\- Brain metastases are cancer cells that have spread to the b...
Location
Multiple Locations
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
PHASE2The purpose of this study is to assess the efficacy, safety, and tolerabili...
Location
Ingalls Memorial Hospital
ANG1005 in Leptomeningeal Disease From Breast Cancer
PHASE3This is an open-label Phase 3 study to see if ANG1005 can prolong survival ...
Location
Multiple Locations
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
PHASE1This is a phase 1, multi-centre, sequential cohort, open-label, dose-escala...
Location
Gabrail Cancer Center